Better Luck Next Time

A federal appeals court ruled against Amgen in the in re Kubin case. In 2000, the US Patent and Trademarks office rejected a patent application submitted by Immunex for the gene encoding the NAIL protein, which plays a role in immune response, because isolating the gene took "routine skill." Amgen, which bought Immunex in the interim, appealed the decision.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.